Gemfibrozil
| Evidence Level: L4 | Predicted Indications: 9 |
Table of Contents
- Gemfibrozil
Gemfibrozil: Rheumatoid arthritis
One-Sentence Summary
Gemfibrozil is a fibrate (PPAR-alpha agonist) originally used to treat hypertriglyceridaemia. The TxGNN model predicts it may be effective for rheumatoid arthritis, but the supporting evidence is limited to preclinical studies and non-specific literature, with no registered clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 0.9990 |
| Evidence Level | L4 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known pharmacology, gemfibrozil is a PPAR-alpha agonist that lowers triglycerides. PPAR agonism also has anti-inflammatory and immunomodulatory effects, such as reduced pro-inflammatory cytokines and modulation of T-cell responses.
This offers a plausible, though indirect, link between a lipid-lowering drug and an autoimmune joint disease. Two preclinical reports support the idea: a 2019 rat adjuvant-induced arthritis study combining gemfibrozil with a reduced steroid dose, and a 2026 study of bezafibrate (a related pan-PPAR agonist) in experimental rheumatoid arthritis. Both are animal studies, and neither shows benefit in people.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 30074417 | 2019 | Preclinical (rat model) | Modern Rheumatology | Gemfibrozil combined with a reduced prednisolone dose gave a similar disease-management picture to the full steroid dose in rat adjuvant-induced arthritis |
| 41207105 | 2026 | Preclinical (related fibrate) | International Immunopharmacology | Bezafibrate, a pan-PPAR agonist, attenuated experimental rheumatoid arthritis via PPAR-dependent modulation of inflammatory pathways, with emphasis on PPAR-gamma activity |
| 18039017 | 2007 | Review | American Journal of Clinical Dermatology | General review of palmar erythema, a clinical sign; only indirectly relevant |
| 20083653 | 2010 | Preclinical (mechanistic) | Journal of Immunology | Myelin basic protein priming reduced Foxp3 expression in T cells via nitric oxide; general autoimmunity mechanism, not specific to rheumatoid arthritis |
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 13618R | Ausgem | Tablet 600 mg (oral) | Indication text not available in the data compiled for this report |
Safety Considerations
- Contraindications flagged in the knowledge graph (these are graph-derived associations, not product label text): liver disease, gallbladder disease, cholelithiasis, cholecystolithiasis, choledocholithiasis, primary biliary cholangitis, impaired renal function, thrombocytopenia, leukopenia, anaemia (including macrocytic anaemia), and Reynolds syndrome.
- Drug interactions: 100 interactions were identified; the 20 listed in the compiled data include these main ones:
- Major: rosuvastatin and simvastatin (the statin combination carries a recognised risk of myopathy and rhabdomyolysis), pioglitazone, repaglinide, loperamide, eluxadoline.
- Moderate: chenodeoxycholic acid, rifaximin, rosiglitazone, nateglinide, chlorpropamide, tolazamide, and multiple insulin products (aspart, degludec, detemir, glargine, glulisine, human insulins). Glucose-lowering agents warrant monitoring for hypoglycaemia.
Please also refer to the TGA-approved Product Information (PI) for full warnings and contraindications, as label-based data were not available.
Conclusion and Next Steps
Decision: Hold
Rationale: Support for rheumatoid arthritis rests on a computational prediction and animal data only. There are no registered clinical trials and no human efficacy data. The high TxGNN score alone does not justify advancing.
To proceed, the following is needed:
- Human clinical evidence (for example, a pilot or Phase 2 study in rheumatoid arthritis)
- Detailed mechanism of action data, particularly the relevance of PPAR-alpha versus PPAR-gamma activity in joint inflammation
- ARTG approved indication text and TGA Product Information warnings and contraindications
- A safety plan covering hepatic and renal function, interactions with statins, and concomitant rheumatoid arthritis therapies (for example, methotrexate and corticosteroids)
Other Predicted Indications (Brief Note)
Two other predictions have some supporting literature, though both are close to gemfibrozil’s existing lipid-modifying use rather than being genuinely new indications:
- HIV protease inhibitor-associated dyslipidaemia (Evidence Level L2): A randomised, double-blind study (PMID 12409741) supports triglyceride lowering. The evidence concerns the metabolic complications of antiretroviral therapy rather than HIV infection itself, and interactions with antiretrovirals and statins need review.
- Hypoalphalipoproteinaemia (Evidence Level L2): Several small clinical studies from 1989 to 2000 show lipoprotein changes, but there are no hard cardiovascular outcome data.
The remaining predictions (rank 2 and ranks 5 to 10) have no supporting trials or literature, or no plausible mechanistic link, and should not be pursued on current evidence.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.